Analyst consensus rating
Aldeyra Therapeutics Analyst Rating: none
Direct answer
Aldeyra Therapeutics's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.60.
Forecast evidence checked October 27, 2026.
Get free Aldeyra Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.64
- Average price target
- $6.60
- High price target
- $13.00
- Low price target
- $2.00
- Low target gap
- +211.9%
- Target upside
- +929.3%
- High target gap
- +1,927.4%
- Target range width
- 1,715.5%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aldeyra Therapeutics?
Aldeyra Therapeutics has a verified none consensus. The same dataset has an average price target of $6.60.
How far are Aldeyra Therapeutics's low and high targets from the recorded price?
The low target implies +211.9%, while the high target implies +1,927.4%.
How many analysts are included in Aldeyra Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Aldeyra Therapeutics's target upside or downside calculated?
The average target of $6.60 is divided by the recorded price of $0.64, then one is subtracted to produce +929.3%. This does not guarantee a future return.
When was Aldeyra Therapeutics's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.